ClinicalTrials.gg
CompletedNCT00051142Updated Aug 5, 2008

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

A Phase 3 interventional study of Travoprost and Latanoprost in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Alcon Research. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-08-05.

Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Started
2001
the only one that year
Phase 3
16 of 46
none open now
Registered
1st of 46
by date
Lead sponsor
29 of 46
Alcon Research

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the only one that started in 2001, is one of 16 in phase 3, and was the 1st registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and IOP-lowering efficacy of Travoprost (0.004%) compared to Latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension.

03

Conditions studied

  • Glaucoma, Open-Angle
  • Ocular Hypertension

Keywords

  • Glaucoma
  • POAG
  • OAG
  • OHT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Adult patients of any race and either sex with open-angle glaucoma (with or without pigment dispersion or pseudoexfoliation component) or ocular hypertension.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double

Interventions

06

Study locations

1 site
  • Latin America
    Fort Worth, Texas, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2001, a primary completion of Jun 2004 and a completion of Jun 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2003
First posted
Jan 7, 2003
Start
Feb 2001
Primary completionActual
Jun 2004
CompletionActual
Jun 2004
Last update
Aug 5, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00051142
Lead sponsor
Alcon Research
First posted
Jan 7, 2003
Start date
Feb 2001
Primary completion
Jun 2004
Completion
Jun 2004
Last update
Aug 5, 2008

Study contacts

Alcon Investigators
principal investigator · Alcon Research
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Travoprost · Latanoprost

Start the discussion